The company said, “Full financial results for the quarter ended March 31, 2025 are in the process of being finalized, however, initial and preliminary results show revenue, driven solely by the TriNav Infusion System, of approximately $9.2 million for the first quarter of 2025. This represents growth of approximately 42% versus the first quarter of 2024. “
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences Announces $22M Private Placement
- TriSalus Life Sciences files to sell 252K shares of common stock for holders
- TriSalus Life Sciences files to sell 91,263 shares of common stock for holders
- TriSalus Life Sciences Reports Strong Growth Amid Challenges
- TriSalus Life Sciences Delays Annual Report Filing
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue